Accessibility Menu
Karyopharm Therapeutics logo

Karyopharm Therapeutics(NASDAQ) KPTI

Current Price$7.16
Market Cap$162.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-97%
5 Year-95%
1 Year+85%
1 Month-20%
Karyopharm Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 7.182026-07-22
Karyopharm Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-24.66%USD 9.532026-07-15
1 month-20.22%USD 9.002026-06-22
3 month-17.94%USD 8.752026-04-23
Year to date-2.45%USD 7.362025-12-31
1 year+84.58%USD 3.892025-07-22
3 year-71.16%USD 24.902023-07-21
5 year-94.59%USD 132.602021-07-23
Since inception-97.02%USD 240.752013-11-06

Karyopharm Therapeutics Financials at a Glance

Market Cap

$162.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$151.12M

Net Income (TTM)

-$194.97M

EPS (TTM)

-$15.09

P/E Ratio

-0.48

Dividend

$0.00

Beta (Volatility)

1.27 (Average)

Price

$7.16

Volume

713,636

Open

$7.92

Previous Close

$7.18

Daily Range

$7.05 - $8.02

52-Week Range

$3.65 - $10.99

Estimated Earnings Date

Aug 10, 2026

KPTI News

using a stethoscope listen to the heartbeat of patient (1)

Why Karyopharm Therapeutics Shares Slumped Thursday

James HalleyMay 4, 2023
Person in a lab looking through a microscope

Why Karyopharm Therapeutics Inched Higher Today

Eric VolkmanAug 4, 2022
life-science-pro-making-selection-getty

Here's Why Karyopharm Therapeutics Is Sliding on Tuesday

Cory RenauerFeb 22, 2022
GettyImages-944545988

Why Karyopharm Therapeutics Stock Was a Winner on Wednesday

Eric VolkmanFeb 9, 2022
angry-investor-2-getty

Why Karyopharm Therapeutics Stock Is Falling Today

Cory RenauerFeb 8, 2022
GettyImages-1207501947

Should You Buy Stock Now in This New Coronavirus Drug Developer?

David HaenApr 29, 2020
Blue poker chips on stock market background

Your 2 Top Profit Opportunities in 2020

Amar KhatriApr 23, 2020
red blood cells abstract

Here's Why Karyopharm Therapeutics Has a Unique Growth Opportunity

Amar KhatriFeb 26, 2020
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Karyopharm Therapeutics

Karyopharm makes new drugs to treat cancer. Its main medicine helps adults with blood cancer. The company uses science to block specific proteins.

What’s in the Medicine Cabinet?

  • Multiple Myeloma Treatment: XPOVIO (selinexor) is an oral medicine for adults with heavily pretreated blood cancer; used after other therapies stop working.
  • SINE Compounds: Selective Inhibitor of Nuclear Export (SINE) molecules designed to trap tumor-suppressing proteins inside cell nuclei; functions by blocking the XPO1 protein.
  • Global Oncology Licensing: Strategic partnerships to sell oncology drugs in Europe, Asia, and Latin America; includes the brand NEXPOVIO for international markets.

Recent Deals and Clinical Steps

  • Partnered with Menarini Group to develop and sell oncology treatments in Europe, the United Kingdom, and Latin America.
  • Entered a securities purchase agreement with RA Capital Healthcare Fund in March 2026, raising $26.9 million in net proceeds.
  • Announced topline results for the Phase 3 SENTRY trial in March 2026; demonstrated significant spleen volume reduction in myelofibrosis patients.
  • Agreed to voluntarily withdraw its accelerated approval for a lymphoma indication in March 2026 following discussions with the FDA.

What Makes the Science Different

Karyopharm focuses on nuclear export, a process that moves proteins between the center and the outer parts of a cell. By targeting XPO1, a protein often overactive in cancer, the company aims to restore the body’s natural ability to fight tumors.

The Latest Financial Scorecard

  • Total revenue reached $35.1 million in Q1 2026, up 16.8% from Q1 2025.
  • Net product revenue grew to $29.2 million in Q1 2026, a 39% increase year-over-year.
  • Net loss reached $22.4 million in Q1 2026, which improved 4.6% from the previous year.
  • Free cash flow hit negative $22.7 million in Q1 2026, an improvement of 41.7% compared to Q1 2025.
  • Cash and cash equivalents totaled $90.9 million as of March 31, 2026.

Bottom Line

Karyopharm is advancing late-stage clinical programs while managing significant debt and high operating costs. The company relies on its core cancer therapy and recent private funding to support its ongoing research and commercial goals.

AI Generated • May 15, 2026

Industry

Biotechnology

Sector

Health Care

Employees

228

CEO

Richard A. Paulson, MBA

Website

www.karyopharm.com

Headquarters

Newton, MA 02459, US

KPTI Financials

Key Financial Metrics (TTM)

Gross Margin

96.03%

Operating Margin

-55.73%

Net Income Margin

-129.02%

Return on Equity

73.11%

Return on Capital

N/A

Return on Assets

-148.36%

Earnings Yield

-2.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$162.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.66M

Volume

713.64K

Avg. Volume

491.22K

Financials (TTM)

Gross Profit

$145.11M

Operating Income

-$84.21M

EBITDA

-$147.92M

Operating Cash Flow

-$59.11M

Capital Expenditure

$0.00

Free Cash Flow

-$59.11M

Cash & ST Invst.

$90.85M

Total Debt

$230.87M

Karyopharm Therapeutics Performance Analysis

Karyopharm Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 157,074,000-25.1%
20232023-12-31USD 146,033,000-7.0%
20242024-12-31USD 145,237,000-0.5%
20252025-12-31USD 146,067,0000.6%
Karyopharm Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3026.4%
Q32025-09-3016.1%
Q42025-12-31-22.6%
Q12026-03-312.9%
Karyopharm Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -30.2822.4%
20232023-12-31USD -18.79-37.9%
20242024-12-31USD -9.41-49.9%
20252025-12-31USD -17.9390.6%
Karyopharm Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-56.0%
Q32025-09-3011.6%
Q42025-12-31-49.0%
Q12026-03-3178.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$35.07M

+16.8%

Gross Profit

$33.71M

+17.4%

Gross Margin

96.13%

N/A

Market Cap

$162.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$713.68K

N/A

Employees

228

N/A

Net Income

-$22.39M

+4.6%

EBITDA

-$9.83M

+20.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$90.85M

+29.9%

Total Debt

$230.87M

+23.7%

Accounts Receivable

$23.36M

-33.7%

Inventory

$3.60M

-24.5%

Long Term Debt

$197.62M

+22.5%

Short Term Debt

$33.25M

+31.0%

Return on Assets

-1.48%

N/A

Return on Invested Capital

-5.97%

N/A

Free Cash Flow

-$22.73M

+41.7%

Operating Cash Flow

-$22.73M

+41.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRSNMersana Therapeutics, Inc.
$29.08+0.00%
INMBINmune Bio, Inc.
$1.84-6.60%
FGENFibroGen, Inc.
$9.07-1.63%
TELOTelomir Pharmaceuticals, Inc. Common Stock
$1.06-1.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.00+0.04%
AALAmerican Airlines Group
$14.79-0.03%
PATHUiPath
$10.70-0.11%
NOKNokia
$10.28-0.03%

Questions About KPTI

What is the current price of Karyopharm Therapeutics?

Karyopharm Therapeutics is trading at $7.18 per share.

What is the 52-week range for Karyopharm Therapeutics?

Over the past 52 weeks, Karyopharm Therapeutics has traded between $3.65 and $10.99.

How much debt does Karyopharm Therapeutics have?

As of the most recent reporting period, Karyopharm Therapeutics reported total debt of $230.87M.

How much cash does Karyopharm Therapeutics have on hand?

Karyopharm Therapeutics reported $90.85M in cash and cash equivalents in its most recent financial results.

What is Karyopharm Therapeutics’s dividend yield?

Karyopharm Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services